whereby inhibitors bind to a heme-containing iNOS monomer species to form an inactive iNOS monomer-heme-inhibitor complex in a pterin-and L-arginine-independent manner. The selectivity for inhibiting dimerization of iNOS versus endothelial and neuronal NOS suggests that the energetics and kinetics of monomer-dimer equilibria are substantially different for the mammalian NOS isoforms. These inhibitors provide new research tools to explore these processes.
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Introduction
The mammalian nitric oxide synthase (NOS) 1 family comprises three isoforms:
cytokine-inducible (iNOS), neuronal (nNOS) and endothelial NOS (eNOS). NOS isoforms are homodimers that catalyze NADPH-dependent oxidation of L-arginine to nitric oxide (NO) and L-citrulline (1) (2) (3) . Each monomer subunit of the dimer comprises a C-terminal reductase domain that contains binding sites for NADPH, FAD, FMN, and calmodulin (CaM), and an N-terminal oxygenase domain which contains binding sites for heme, tetrahydrobiopterin (H 4 B), and L-arginine (3-7). As in cytochrome P-450, the NOS heme iron coordinates to the protein through a cysteine thiolate (6) (7) (8) , binds O 2 as a sixth ligand (9) , and participates directly in catalysis (9) (10) (11) (12) (13) . The heme ligands CO, 5 Highly potent and selective pyrimidineimidazole-based iNOS dimerization inhibitors were discovered via a combinatorial chemistry approach using a cell-based iNOS assay (30) . Crystallographic studies showed that the inhibitors coordinate the heme in the iNOS monomer, disrupt helix 7a and displace the critical arginine-binding Glu-371
residue from the active site. In addition helix 8, which is part of the dimer interface, is partially disordered by inhibitor binding. These results suggest that inhibitor binding to iNOS monomer prevents formation of both arginine and H 4 B binding sites and leads to the formation of a "dead-end" inhibitor-monomer complex.
Interestingly, while the inhibitors led to accumulation of iNOS monomers in cells, they did not inhibit the catalytic activity of isolated dimeric iNOS. In the present study, biochemical characterization of these inhibitors with isolated human and murine iNOS monomers are presented. In addition, the binding kinetics of these inhibitors to iNOS monomers was determined using a high affinity radiolabeled inhibitor in a rapid-filtration binding assay. Binding affinity in this assay correlated with inhibitory potency in cell culture. The results provide further insights into the mechanism of action of these novel inhibitors and introduce new reagents to study iNOS monomer-dimer equilibria.
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). The C 18 HPLC column was from Column Engineering (Ontario, CA). The Speed Vac Concentrator was purchased from Savant (Holbrook, NY).
Protein Assay and Heme Content of iNOS Monomer Preparations
Protein content of purified NOS monomer preparations was determined using the method of Bradford according to the manufacturer's instructions (BioRad, Richmond, CA) using bovine serum albumin as standard. The heme content of purified full-length human iNOS monomer preparations was determined spectrally by comparing the absorbance changes due to arginine or imidazole binding with that of pure human iNOS oxygenase domain (iNOSox) which had its heme content determined by the reduced pyridine hemochrome assay and by Soret band intensity upon binding of carbon monoxide (33) . Dimeric iNOSox preparations which had a concentration of 10 µM heme-bound protein showed an increase at 400 nm and a decrease at 428 nm when excess arginine (1 mM) was added to imidazole-bound material (imidazole was first added to 0.25 mM). This difference, or (A 400 -A 428 ) was 0.40 OD units for 10 µM iNOSox. 2.58 µM full-length human iNOS monomer preparations had an (A 400 -A 428 ) value of 0.010 OD units under the same conditions, hence the heme content was 0.25 µM, or about 10%.
Using the (A 400 -A 428 ) difference gave a more reliable measurement of heme content than absolute A 428 for the human iNOS monomer preparations due to their low heme content and interference from bound flavins.
The heme content of murine iNOS monomer preparations was measured using the absorbance (corrected for light scattering) at 428 nm of imidazole-bound enzyme. Using this method, in which an A 428 value of 0.48 was measured for 10 µM heme in dimeric iNOSox, the heme content of full-length murine iNOS monomer, which was prepared by the dissociation of dimeric iNOS by urea, was about 95%, and of mouse ∆114-iNOS-ox monomer was about 85%.
iNOS Dimerization Assay
Dimerization of purified human iNOS monomer was performed by incubating the protein (0.6 µM) in NOS assay buffer (40 mM Bis-tris propane, 4 µM FAD, 4 µM FMN, 4 µM H 4 B, 5 mM reduced glutathione, pH 7.8) containing 5 mM arginine, with or without 1.2 µM calmodulin and/or 0.6 µM hemin chloride as noted in Results. The mixture was incubated for 2.5 hours at 37°C, or at various time points as described in Results.
Compound 2 (2 µM) was added just prior to initiation of dimerization. For the experiment in Figure 2C , the assay buffer also included 0.05 mg/ml BSA and 0.01%
Triton X-100 in order to prevent adsorption of protein on polypropylene surfaces. After the 2.5-hour incubation, NO synthesis was measured using the colorimetric Griess assay for nitrite (34) , as follows. Additional arginine (0.75 mM final concentration) and NADPH (1 mM final concentration) were added. After incubation for 30 minutes at 37°C , the reaction was stopped by the addition of lactate dehydrogenase (60 units/ml) and 66 mM sodium pyruvate followed by incubation for 15 minutes at room temperature.
50 µl Griess reagent (2% sulfanilamide, 0.2% N-(1-naphthyl) ethylenediamine, 5% phosphoric acid) was then added to 150 µl reaction aliquots, and the absorbance at 550 nm was read after 5 minutes. Nitrite concentration was determined against a sodium nitrite standard from 0 to 65 µM. The background signal was due to dimer formation that occurred during the 30 minute incubation with NOS monomer that was not incubated with arginine during the initial 2.5 hour step.
Gel Filtration Chromatography
Gel filtration chromatography of dimerization assay aliquots was performed on a Superdex 200 3.2/30 column using the Pharmacia SMART system. 50 µl aliquots of dimerization mix after 2.5 hour incubation at 37°C, prepared as described above except using 3 µM iNOS monomer, 2 µM calmodulin and 1.5 µM hemin, were loaded on the column and chromatographed at 40 µl/min in PBS (25 mM Na phosphate, 150 mM NaCl, pH 7.2.) 
Synthesis of Radioligand

Cell-Based Assays
The cell-based assay using A-172 human glioblastoma cells was performed as 
Spectral Studies
HP8452A spectrophotometer using 0.4-ml sample volumes in quartz cuvettes with 1 cm path-length. iNOS monomer isolated from murine macrophage (RAW264.7) cells was used because it had a higher heme content than human iNOS monomer preparations, having been prepared by the dissociation of dimeric iNOS using urea. Full-length murine iNOS monomer at 2 µM was placed in a cuvette and the spectrum from 350 to 500 nm was measured. The spectrum was taken before and ten minutes after addition of 10 µM
Compound 2. Inhibitor binding resulted in a decrease in absorbance at 400 nm and an increase at 428 nm.
RESULTS
Dimerization Assay using Purified iNOS Monomers
Fig . 1 shows the structures of the compounds used in the present study. The potent and selective pyrimidineimidazole-based inhibitors of iNOS dimerization were discovered using a cell-based assay and found not to inhibit the enzymatic activity of purified dimeric iNOS (30) . In order to study dimerization of iNOS in a purified system, slight modifications of the method described by Baek et al. (18) Generation of active dimeric human iNOS was concentration-dependent, with 0.6 µM monomer forming enough dimeric iNOS activity to measure using the Griess reagent, and with concentrations less than 0.1 µM not giving an appreciable signal (data not shown). Fig. 2B shows that the starting iNOS monomer preparation contained less than 5% dimeric iNOS (panel 1) despite the presence of 4 µM H 4 B during isolation.
Incubation of monomeric iNOS for 2.5 hours at 37°C with H 4 B, but without arginine produced minimal dimeric NOS (panel 2). However, when arginine was added, a significant amount of dimeric iNOS was produced (panel 3). The enzymatic activity increased as dimeric NOS was formed, and this activity was inhibited by 2 µM
Compound 2 added at the start of the dimerization reaction ( 
Inhibition of iNOS in Cell-based Assays
Crystallography studies indicate that inhibitor binding prevents formation of the a radiolabeled compound with a specific activity of ~100 Ci/mmole. The incorporation of radiolabel at the secondary nitrogen of the piperazine ring was selected on the basis of structure-activity relationships in the A-172 cell-based assay, which showed that this region was not essential for inhibitor activity 3 . This was subsequently confirmed by Xray crystallographic data showing that this region of the inhibitor is exposed to solvent and not involved in iNOS monomer-inhibitor binding interactions (30) . 
Changes in Absorbance Spectra due to Compound Binding
Spectral studies (Fig. 8) show that like imidazole, the pyrimidineimidazole inhibitors cause a shift of the heme iron of murine iNOS monomer to a low-spin state (absorbance maximum at 428 nm), which is characteristic of binding to the iron as a sixth ligand (37) .
DISCUSSION
Novel pyrimidineimidazole-based iNOS inhibitors previously identified using a cell-based assay (30) are shown here to inhibit dimerization of purified iNOS monomers.
In addition, a high-affinity radiolabeled inhibitor was used to develop a rapid-filtration binding assay using purified human and murine iNOS monomers. This binding assay had a broad dynamic range, allowing for inhibitor affinities to be measured in the pM to µM range and also exhibited good correlation with inhibitor potency in the cell-based assay.
The biochemical results are consistent with the pyrimidineimidazoles forming a highaffinity complex with iNOS monomers via heme ligation, as evidenced by spectral perturbations and competition with the known iNOS heme ligands imidazole, clotrimazole and miconazole.
While human iNOS monomer-dimer ratios have been studied in cell lysates (38, 39) , the present work is the first to describe human iNOS dimer formation from purified iNOS monomers. The results are thus discussed relative to published studies with murine iNOS monomers. During purification, the mammalian cell-expressed human iNOS monomers were separated from dimeric iNOS using gel filtration chromatography, in the presence of 4 µM H 4 B at 4°C, and were stored frozen immediately after elution from the column. Despite the presence of 4 µM H 4 B, the iNOS monomer preparation contained little dimeric iNOS at the start of the in vitro dimerization assay, and little active iNOS dimer was formed in the presence of H 4 B alone. Thus, the substrate Larginine rather than H 4 B appeared to promote human iNOS dimerization under the conditions used. As shown in Fig. 2B , not all of the human iNOS monomers could be dimerized even in the presence of excess arginine, H 4 B, heme and calmodulin. The data are consistent with the human iNOS monomer preparations containing a mixture of heme-bound (~ 10%) and heme-free (~ 90%) species and that only the heme-bound species is capable of dimerizing. An implication of these findings is that a large proportion of the recombinant human iNOS monomers isolated from cells have no bound heme and cannot bind exogenously added heme. These are likely to be denatured species that cannot dimerize. The murine iNOS monomer used in the present studies, which was prepared by dissociation of dimeric iNOS with urea, does not require added heme to dimerize, in contrast to previously published results using monomers isolated directly from mouse macrophage cells (18). As the murine iNOS monomer preparation is already 95% heme-containing (see Experimental Procedures), a requirement for added heme to promote dimerization would not be expected.
In relation to time course, arginine-and H 4 B-dependence, the results with human iNOS are comparable to previous studies using full-length murine iNOS monomer (18, 40) and murine iNOS oxygenase domain monomer (24) . In these studies, dimerization was minimal with the addition of H 4 B alone as compared to the addition of both H 4 B and arginine. However, in other studies using murine iNOS oxygenase domain (28, 41) or full-length iNOS monomers (41), the extent of dimerization observed with H 4 B alone was about 50% (28) to over 80% (41) of that seen with both H 4 B and arginine. These disparate results may reflect differences in the procedures for monomer isolation.
The affinity and reactivity of pyrimidineimidazoles with human and murine iNOS is distinct from previously reported imidazole-containing iNOS inhibitors. The novel compounds used in this study (see Fig. 1 ) are derivatized pyrimidineimidazoles with a bulky side chain that interacts with the iNOS monomer at a separate site from the imidazole-heme interaction (30) . Smaller compounds such as imidazole, 1-phenylimidazole and 7-nitroindazole, actually promote dimerization (40) . Unlike the pyrimidineimidazoles described here, all of these smaller compounds inhibit the activity of dimeric iNOS (14) . The heme iron of iNOS monomers can bind large 1-substituted imidazoles with affinity in the micromolar range, consistent with the observation that iNOS monomers contain a relatively open distal heme pocket. The antifungal imidazoles clotrimazole and miconazole prevent iNOS dimerization (40) , presumably due to steric hindrance from the aromatic side chains (Fig. 1) . The 1000-fold higher affinity of the pyrimidineimidazoles for iNOS monomers over clotrimazole and miconazole is presumably due to specific interactions with residues in the iNOS monomer. The crystal structure of Compound 2 bound to monomeric ∆114-iNOS-ox (30) reveals that the free imidazole nitrogen coordinates directly to the heme and the benzodioxolane group makes specific contacts with the iNOS monomer, thereby disrupting the arginine-binding site.
Compound 2 also disrupts helix 7a and helix 8, which are part of the iNOS dimer interface. These findings predict the formation of a "dead-end" inhibitor complex that should not be prevented by excess arginine or H 4 B in cell culture medium. IC 50 determinations for Compound 2 in the cell-based assays confirm this hypothesis.
A general model for iNOS dimer assembly and its inhibition by these compounds is shown in Fig. 9 and is similar to that proposed for the effects of antifungal imidazoles on murine iNOS (40) . Heme insertion is the first step in dimerization (18, 19, 42) .
Binding of heme leads to the formation of a loosely formed dimer ("DIMER-Fe") which then binds H 4 B and arginine to form a stable, compact enzymatically active dimer ("DIMER-Fe-H 4 B-Arg"). The pyrimidineimidazoles do not inhibit the activity of dimeric iNOS even after prolonged incubation (IC 50 > 100 µM) 3 . In addition, spectral binding experiments with purified iNOS confirm high affinity binding to iNOS monomers (K s < 50 nM), but low affinity binding to iNOS dimers (K s > 10 µM) 4 . The correlation between human monomer heme content and inhibitor binding sites from Scatchard analysis,
indicates that inhibitors do not bind to heme-free, but rather to heme-containing iNOS monomers. Thus, in cells, these inhibitors act by binding to a transient species that, in the absence of compound, would rapidly dimerize. In the presence of compound, monomeric iNOS is trapped in a nonfunctional monomer-heme-inhibitor complex. An implication of our findings is that in cell culture systems the equilibrium between the heme-containing monomer species and the dimer is in favor of the dimer and that once stable iNOS dimers are formed there is little dissociation back to monomers. This is supported by the finding that iNOS monomer isolated from murine macrophages is heme-free, whereas all hemecontaining iNOS is dimeric (18). The ability of the pyrimidineimidazoles to bind and destabilize the proposed "loose" iNOS dimer that is H 4 B-and arginine-free, remains to be determined.
Previously the pyrimidineimidazoles were shown to exhibit high selectivity (> 1000-fold) for inhibiting iNOS versus eNOS dimerization, whereas the selectivity ratio for nNOS was only ~ 5-fold for Compound 2 (30) . High eNOS selectivity is retained for all of the pyrimidineimidazoles shown in Fig.1 , whereas nNOS selectivity ranges from 5 to 100-fold and is altered by changing the substituents on the pyrimidineimidazole core 5 .
These results indicate that the compounds exhibit specific affinity for the iNOS and nNOS monomers, but may not have appreciable affinity for eNOS monomers. The molecular basis for this isoform selectivity is not readily apparent from analysis of the crystal structures of the active sites of the NOS isoforms.
It is also noted that there is an inverse relationship between the stability of the iNOS, nNOS and eNOS dimers and the isoform selectivity of these pyrimidineimidazoles. It is reported that eNOS dimers are the most stable, nNOS next, and iNOS dimers the least stable, as measured by dimer resistance to chaotropes such as urea or SDS (42) (43) (44) . Thus, in addition to binding specificity, the NOS isoform selectivity may be partially explained by considering the energetics that drive NOS monomer-dimer equilibria. With the other isoforms relative to iNOS, the free energy difference between heme-containing monomer and dimer is larger and thus the steady state monomer-dimer equilibrium progresses in favor of dimer formation in the order eNOS >> nNOS > iNOS.
In a competition between the formation of dimer and the formation of a monomerinhibitor complex, the amount of inhibitor required to effectively compete is dependent upon this equilibrium, and therefore is much greater for eNOS than nNOS or iNOS. It is thus formally possible that the inhibitors have appreciable affinity for eNOS monomers, but inhibition is not observed due to the eNOS monomer-dimer equilibrium. The model also predicts that the set point for the eNOS monomer ↔ dimer equilibrium is very heavily in favor of eNOS dimer and that the transient eNOS monomer species with bound heme will be very difficult to isolate. This is consistent with repeated unsuccessful attempts to isolate native heme-containing eNOS monomers using chaotropes that readily provide iNOS and nNOS monomers 6 .
Regarding the general pharmacological selectivity of the pyrimidineimidazoles, Log CPM
